Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials

Journal of Endocrinological Investigation

Volumn 40, Issue 11, 2017, Pages 1251-1258

  Monami, M ^a   Nreu, B ^a   Scatena, A ^b   Giannini, S ^a   Andreozzi, F ^c   Sesti, G ^c   Mannucci, E ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Atrial fibrillation; GLP 1 receptor agonists; Meta analysis

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; LIRAGLUTIDE; LIXISENATIDE; SEMAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ARTICLE; ATRIAL FIBRILLATION; DESCRIPTIVE RESEARCH; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; AGONISTS; METABOLISM; PATHOLOGY; PROGNOSIS;

ATRIAL FIBRILLATION; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85020091693     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-017-0698-7     Document Type: Article

References (22)

1. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, ELIXA Investigators (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:2247–2257
2. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial Investigators (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322
3. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T, SUSTAIN-6 Investigators (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844
4. Marso SP, Lindsey JB, Stolker JM, House JA, Martinez Ravn G, Kennedy KF et al (2011) Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2:3 liraglutide clinical development studies. Diabetes Vasc Dis Res 8:237–240
5. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L (2011) Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 10:22
6. Seshasai SR, Bennett RL, Petrie JR, Bengus M, Ekman S, Dixon M et al (2015) Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. Diabetes Obes Metab 17:505–510
7. Fisher M, Petrie MC, Ambery PD, Donaldson J, Ye J, McMurray JJ (2015) Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol 3:697–703
8. Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Quan X, Ji L, Zhan S (2015) Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract 110(1):26–37
9. Smits MM, Muskiet MH, Tonneijck L, Hoekstra T, Kramer MH, Diamant M, van Raalte DH (2016) Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males. Br J Clin Pharmacol 81:613–620
10. ®). https://clinicaltrials.gov/ct2/show/NCT01179048?term=leader+liraglutide&rank=2. Accessed 30 Nov 2016
11. http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015020245. Accessed 3rd Nov 2016
12. http://www.fda.gov. Accessed 3rd Nov 2016
13. http://www.ema.europa.eu/ema/. Accessed 3rd Nov 2016
14. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101
15. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple graphical test. BMJ 315:629–634
16. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269
17. Lorenz M, Lawson F, Owens D, Raccah D, Roy-Duval C, Lehmann A, Perfetti R, Blonde L (2017) Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol 16:6
18. Kedem J, Sonn J, Scheinowitz M, Weiss HR (1989) Relationship between local oxygen consumption and local and external cardiac work: effect of tachycardia. Cardiovasc Res 23:1043–1052
19. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E (2014) Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16:38–47
20. Fisher M, Petrie MC, Ambery PD, Donaldson J, Ye J, McMurray JJ (2015) Cardiovascular safety of albiglutide in the harmony programme: a meta-analysis. Lancet Diabetes Endocrinol 3:697–703
21. Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, Mannucci E (2017) Safety issues with glucagon-like peptide-1 receptor agonists: pancreatitis, pancreatic cancer, and cholelithiasis data from randomised controlled trials. Diabetes Obes Metab. doi:10.1111/dom.12926
22. Monami M, Zannoni S, Pala L, Silverii A, Andreozzi F, Sesti G, Mannucci E (2017) Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Int J Cardiol. doi:10.1016/j.ijcard.2017.03.163